Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | Chief Development Officer | August 12, 2025 | August 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edgewise Therapeutics, Inc.
Report date August 12, 2025 · Filed August 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2035-08-12 | Direct | 17,500 |
Reported balance
After 2025-08-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-08-12 · Grant · Acquired 17,500 · Balance 17,500 F1: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.39 · Expires 2035-08-12 | Direct | 105,000 |
Reported balance
After 2025-08-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-08-12 · Grant · Acquired 105,000 · Balance 105,000 F2: 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
F2: 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2025 Filed Aug 14, 2025 19:44 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Options (Right to buy) · Derivative | 105,000 | $0.00 Strike: $13.39 | $0.00 |
DisclosureSEC source: 0001562180-25-005800 · primarydocument.xml · derivative · entry 2 Blaustein Robert · CIK 0002053149 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2035-08-12 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 19:44 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 17,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005800 · primarydocument.xml · derivative · entry 1 Blaustein Robert · CIK 0002053149 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2035-08-12 F1 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 19:56 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Options (Right to buy) · Derivative | 160,000 | $0.00 Strike: $27.39 | $0.00 |
DisclosureSEC source: 0001562180-25-000497 · primarydocument.xml · derivative · entry 2 Blaustein Robert · CIK 0002053149 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2035-01-21 F2 · derivative.exercise_date: 1/4th of the shares subject to the option become vested and exercisable on January 21, 2026 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 19:56 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000497 · primarydocument.xml · derivative · entry 1 Blaustein Robert · CIK 0002053149 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-01-21 F1 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on January 21, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.